Total Funding
50
Total FundingPost-IPO Equity raised
Growth Score
pts
Heat Score
-7 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
202804
SanBio is a regenerative medicine company that provides research, development, production, and sales of regenerative cell medicines.
Toshimichi Ueda: External Auditor- Akihiro Tsujimura: Corporate Officer Senior Management Director, SanBio Inc CEOPast Role: Santen Pharmaceutical, Executive Corporate Officer
About the Company
SanBio is a regenerative medicine company with cell-based products in various stages of research, development, and clinical trials. Its proprietary cell-based product, SB623, is currently in a Phase 2b clinical trial for treatment of chronic motor impairments resulting from stroke with its joint development partner, Sumitomo Dainippon Pharma Co.,
Ltd., in the United States and Canada. SanBio is also implementing a global Phase 2 clinical trial in the United States and Japan using SB623 for treatment of motor impairment resulting from traumatic brain injury.
